Product Code: ETC7542881 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The India Etanercept market is experiencing steady growth due to the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis in the country. Etanercept, marketed under various brand names, is a biologic therapy that helps reduce inflammation and provide relief to patients suffering from these conditions. The market is driven by factors such as rising healthcare expenditure, growing awareness about advanced treatment options, and the availability of biosimilar versions of Etanercept at lower costs. Key players in the India Etanercept market include multinational pharmaceutical companies and domestic manufacturers, who are investing in research and development activities to introduce new products and expand their market presence. The market is expected to continue its growth trajectory as more patients opt for biologic therapies to manage chronic autoimmune diseases effectively.
The India Etanercept market is experiencing steady growth due to the increasing prevalence of autoimmune diseases such as rheumatoid arthritis and psoriasis. The market is driven by factors such as a growing aging population, rising healthcare awareness, and improving access to advanced treatments. Additionally, the increasing adoption of biologic therapies and advancements in healthcare infrastructure are contributing to the expansion of the Etanercept market in India. There is a significant opportunity for pharmaceutical companies to invest in research and development of new formulations and delivery methods for Etanercept to cater to the evolving needs of patients. Collaborations with healthcare providers and the introduction of patient assistance programs can further enhance market penetration and patient access to Etanercept therapies.
In the India Etanercept Market, several challenges are faced, including the presence of alternative treatment options, affordability issues due to the high cost of biologic drugs, and limited awareness among patients and healthcare professionals about the benefits of Etanercept. Regulatory hurdles and intellectual property issues also pose challenges for market growth. Additionally, the lack of proper infrastructure and skilled healthcare professionals for administering biologic therapies further hinders market expansion. Moreover, the competitive landscape with the presence of other biologic drugs targeting similar indications adds to the challenges faced by Etanercept manufacturers in India. Overall, overcoming these obstacles requires strategic pricing strategies, increased awareness campaigns, and investments in healthcare infrastructure and talent development.
The India Etanercept Market is primarily driven by factors such as a growing prevalence of autoimmune diseases like rheumatoid arthritis, psoriasis, and ankylosing spondylitis in the country. Increasing awareness and diagnosis rates of these conditions, coupled with a rising geriatric population prone to such diseases, are also contributing to the market`s growth. Additionally, advancements in healthcare infrastructure, availability of innovative biologic therapies, and a shift towards more personalized treatment approaches are further boosting the demand for etanercept in India. Government initiatives to improve access to healthcare services and a growing emphasis on early intervention and disease management are expected to sustain the market`s momentum in the coming years.
The Indian government has implemented various policies related to the Etanercept market to promote accessibility and affordability of this biologic drug. The government has allowed for the import and sale of Etanercept by both domestic and international pharmaceutical companies, subject to regulatory approval from the Central Drugs Standard Control Organization (CDSCO). In addition, the government has taken steps to encourage the development of biosimilars of Etanercept to increase competition and lower prices. Furthermore, the government has included Etanercept in the National List of Essential Medicines (NLEM), ensuring its availability in public healthcare facilities at subsidized rates. These policies aim to improve access to Etanercept for patients with autoimmune diseases such as rheumatoid arthritis and psoriasis across India.
The India Etanercept market is expected to witness steady growth in the coming years, driven by factors such as increasing prevalence of autoimmune diseases like rheumatoid arthritis and psoriasis, growing healthcare infrastructure, and rising awareness about advanced treatment options. The market is likely to benefit from the introduction of biosimilar versions of Etanercept, which are expected to offer cost-effective alternatives to the branded drug. Additionally, collaborations between pharmaceutical companies and research institutions for the development of innovative therapies and expanding patient access to treatment are anticipated to further fuel market growth. However, challenges such as stringent regulatory requirements and pricing pressures may hinder the market expansion to some extent. Overall, the India Etanercept market is poised for growth opportunities in the foreseeable future.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Etanercept Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Etanercept Market Revenues & Volume, 2021 & 2031F |
3.3 India Etanercept Market - Industry Life Cycle |
3.4 India Etanercept Market - Porter's Five Forces |
3.5 India Etanercept Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 India Etanercept Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 India Etanercept Market Revenues & Volume Share, By Dosage, 2021 & 2031F |
3.8 India Etanercept Market Revenues & Volume Share, By Route Of Administration, 2021 & 2031F |
4 India Etanercept Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases in India |
4.2.2 Growing adoption of biologic drugs for treating chronic diseases |
4.2.3 Rising healthcare expenditure and improving healthcare infrastructure in India |
4.3 Market Restraints |
4.3.1 High cost associated with etanercept treatment |
4.3.2 Stringent regulatory requirements for approval and marketing of biologic drugs in India |
5 India Etanercept Market Trends |
6 India Etanercept Market, By Types |
6.1 India Etanercept Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 India Etanercept Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 India Etanercept Market Revenues & Volume, By Enbrel, 2021- 2031F |
6.1.4 India Etanercept Market Revenues & Volume, By Benepali, 2021- 2031F |
6.1.5 India Etanercept Market Revenues & Volume, By Others, 2021- 2031F |
6.2 India Etanercept Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 India Etanercept Market Revenues & Volume, By Ankylosing Spondylitis, 2021- 2031F |
6.2.3 India Etanercept Market Revenues & Volume, By Rheumatoid Arthritis, 2021- 2031F |
6.2.4 India Etanercept Market Revenues & Volume, By Psoriatic Arthritis, 2021- 2031F |
6.2.5 India Etanercept Market Revenues & Volume, By Others, 2021- 2031F |
6.3 India Etanercept Market, By Dosage |
6.3.1 Overview and Analysis |
6.3.2 India Etanercept Market Revenues & Volume, By Injection, 2021- 2031F |
6.3.3 India Etanercept Market Revenues & Volume, By Solution, 2021- 2031F |
6.3.4 India Etanercept Market Revenues & Volume, By Others, 2021- 2031F |
6.4 India Etanercept Market, By Route Of Administration |
6.4.1 Overview and Analysis |
6.4.2 India Etanercept Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.4.3 India Etanercept Market Revenues & Volume, By Others, 2021- 2031F |
7 India Etanercept Market Import-Export Trade Statistics |
7.1 India Etanercept Market Export to Major Countries |
7.2 India Etanercept Market Imports from Major Countries |
8 India Etanercept Market Key Performance Indicators |
8.1 Patient adherence rate to etanercept therapy |
8.2 Number of healthcare providers trained in prescribing etanercept |
8.3 Rate of new product development and market approval in the biologics segment |
9 India Etanercept Market - Opportunity Assessment |
9.1 India Etanercept Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 India Etanercept Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 India Etanercept Market Opportunity Assessment, By Dosage, 2021 & 2031F |
9.4 India Etanercept Market Opportunity Assessment, By Route Of Administration, 2021 & 2031F |
10 India Etanercept Market - Competitive Landscape |
10.1 India Etanercept Market Revenue Share, By Companies, 2024 |
10.2 India Etanercept Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |